Home / Register for webinar: Embracing scientific complexity to mitigate toxicity issues and development risks while advancing toward the clinic
Register for webinar: Embracing scientific complexity to mitigate toxicity issues and development risks while advancing toward the clinic
Join us on April 1st, 2026 at 3:00 PM CEST / 2:00 PM BST / 9:00 AM ET for this live webinar.
Key Learnings:
- Understand how increasing molecular complexity can influence a compound series’ overall profile, including both on- and off-target effects.
- Explore how early investment in synthesis methodology can deliver downstream benefits during development and scale-up.
- Identify key CMC decision points needed to generate the right data to support clinical development timelines.
- Incorporate CMC developability considerations early to help keep programs progressing efficiently.
Who this webinar is designed for:
CMC scientists and development leads
responsible for planning synthesis, scale-up, and development strategy.
Drug discovery and development teams
working with increasingly complex molecules.
Project leaders and technical decision-makers
involved in preparing programs for clinical development.
Meet the Speakers
Goran Verspui Head of Drug Development, Symeres
Goran Verspui joined Symeres in 2005 and currently serves as Head of Drug Development. In this role, he oversees a broad range of development activities, typically beginning at clinical candidate selection. His team supports programs through early-phase scale-up, solid-state R&D, chemical and analytical development, drug substance manufacturing, formulation development, clinical manufacturing, and regulatory support.
Goran is an organic chemist who received his PhD from Delft University of Technology, where he worked under the supervision of the late Professor Roger Sheldon. His doctoral research focused on catalytic systems for pharmaceutical intermediates and polymers, where Green Chemistry principles became a foundational element of his professional approach.
Throughout his career, Goran has applied high-throughput experimentation and modelling techniques to accelerate the development and optimization of complex chemical transformations. At Symeres, these approaches have been further developed and integrated into the company’s drug development services.
Goran has worked with a wide range of clients, from early-stage biotech start-ups to large pharmaceutical companies. He is particularly motivated by the pace and evolving strategy of early drug development, where rapid decision-making and scientific insight are critical to success.
James Lanter Principal, 8D MedChem, LLC
James Lanter is a Principal at 8D MedChem, LLC. He brings extensive experience from a career that began in large pharmaceutical organizations before moving into smaller biotechnology environments.
Through this transition, James developed first-hand insight into the changing needs of emerging biotech companies, particularly the growing importance of external partnerships and outsourcing to access specialized expertise.
His experience across both large pharma and smaller biotech settings provides a valuable perspective on how organizations can navigate complex development challenges while building effective collaborations.
